Table 3.
The number and proportion of patients who underwent a specific initial treatment approach for prostate cancer from 2005 to 2016.
| Yr | 2005–2006 | 2007–2008 | 2009–2010 | 2011–2012 | 2013–2014 | 2015–2016 |
|---|---|---|---|---|---|---|
| Watchful waiting (%) | 4 (5.6) | 9 (5.6) | 3 (1.8) | 2 (1.3) | 1 (0.7) | 3 (2.1) |
| Active surveillance (%) | 10 (14.1) | 31 (19.4) | 40 (24.4) | 51 (32.1) | 35 (24.5) | 32 (22.5) |
| RP | ||||||
| Open RP (%) | 40 (100.0) | 91 (100.0) | 90 (97.8) | 51 (70.8) | 2 (2.4) | 4 (5.1) |
| Robotic RP (%) | 0 (0.0) | 0 (0.0) | 2 (2.2) | 21 (29.2) | 80 (97.6) | 75 (94.9) |
| Total RP (%) | 40 (56.3) | 91 (56.9) | 92 (56.1) | 72 (45.3) | 82 (57.3) | 79 (55.6) |
| PLND (%) | 18 (45.0) | 74 (81.3) | 69 (75.0) | 51 (70.8) | 45 (54.9) | 19 (24.1) |
| no PLND (%) | 22 (55.0) | 17 (18.7) | 23 (25.0) | 21 (29.2) | 37 (45.1) | 60 (75.9) |
| ADT therapy | ||||||
| LHRH agonist (%) | 13 (100.0) | 18 (100.0) | 16 (100.0) | 14 (100.0) | 12 (85.7) | 3 (30.0) |
| LHRH antagonist (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 2 (14.3) | 7 (70.0) |
| Total ADT therapy (%) | 13 (18.3) | 18 (11.2) | 16 (9.8) | 14 (8.8) | 14 (9.8) | 10 (7.0) |
| Radiotherapies | ||||||
| EBRT | 0 (0.0) | 2 (25.0) | 1 (9.1) | 1 (7.1) | 2 (33.3) | 4 (57.1) |
| HDR brachytherapy | 1 (100.0) | 6 (75.0) | 6 (54.5) | 5 (35.7) | 0 (0.0) | 0 (0.0) |
| LDR brachytherapy | 0 (0.0) | 0 (0.0) | 4 (36.4) | 8 (57.1) | 4 (66.7) | 3 (42.9) |
| Total radiotherapies (%) | 1 (1.4) | 8 (5.0) | 11 (6.7) | 14 (8.8) | 6 (4.2) | 7 (4.9) |
| Space-Oar (%) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (57.1) | 5 (83.3) | 4 (57.1) |
| Fiducial seeds (%) | 0 (0.0) | 6 (75.0) | 2 (18.2) | 10 (71.4) | 5 (83.3) | 5 (71.4) |
ADT, androgen deprivation therapy; EBRT, external beam radiation therapy; HDR, high dose rate; LDR, low dose rate; LHRH, luteinizing hormone receptor hormone; PLND, pelvic lymph node dissection; RP, radical prostatectomy.